PRA Health Sciences Late Phase Services is participating in a global real world safety study program, mandated by various regulatory bodies, to confirm risk/benefit profile for a novel oral anticoagulant to assess the drug’s bleeding risk. Our ability to provide global operational oversight and efficiencies, ensure consistent communication with sites, and keep our patients engaged resulted in PRA becoming the client’s CRO of choice.
Is Marijuana a Replacement for Opioids?
Meeting Enrollment Goals Breast Cancer
An open-label, randomized, multi-center study to evaluate the use of Study Drug in the prevention of cancer treatment-related bone loss in…
Join PRA in China
The expertise of a global CRO + local know-how to deliver the highest caliber of clinical development services around the world.